[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-346367-105":59,"doc-detail-346367-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","potent-synthetic-lethality-between-plk1-and-eya-family-inhibitors-in-tumors-of-the-central-and-peripheral-nervous-systems-research-report","Potent synthetic lethality between PLK1 and EYA family inhibitors in tumors of the central and peripheral nervous systems - Research report","","The Eyes Absent (EYA1–4) protein phosphatase family is aberrantly expressed and promotes tumor growth in cancers of the central and peripheral nervous systems. Building on evidence that EYA1 and EYA4 enhance the active pool of PLK1 molecules, the study tests therapeutic combination strategies pairing EYA inhibitors with direct ATP-competitive PLK1 inhibitors. Combined inhibition drives loss of viability, reduces PLK1 activity and RAD51 focus formation, and increases mitotic arrest and cell death, including in glioblastoma stem cell models.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/potent-synthetic-lethality-between-plk1-and-eya-family-inhibitors-in-tumors-of-the-central-and-peripheral-nervous-systems-research-report/346367/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/potent-synthetic-lethality-between-plk1-and-eya-family-inhibitors-in-tumors-of-the-central-and-peripheral-nervous-systems-research-report/346367.png","ImageObject",300,407,{"name":92,"@type":93},"Himbo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What is the central hypothesis of the study?","Question",{"text":112,"@type":113},"EYA family inhibitors are hypothesized to indirectly inhibit PLK1 by reducing the active PLK1 pool, thereby sensitizing tumors to direct ATP-competitive PLK1 inhibitors and producing synthetic lethality.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does combined EYA and PLK1 inhibition affect cancer cells?",{"text":117,"@type":113},"The combination causes potent loss of cell viability, decreases PLK1 activity and RAD51 focus formation, and increases mitotic arrest and cell death in EYA-overexpressing cancer models.",{"name":119,"@type":110,"acceptedAnswer":120},"Does the combination work in glioblastoma stem cell models?",{"text":121,"@type":113},"Yes. The combined EYA and PLK1 inhibition is effective in glioblastoma stem cell models that overexpress EYA1/EYA4 and it specifically targets the cancer stem cell state.",{"name":123,"@type":110,"acceptedAnswer":124},"Which molecular features are linked to sensitivity to the combination?",{"text":125,"@type":113},"Multiomic correlational analysis identifies high levels of the NuRD complex and SOX9 as contributors to sensitivity to the combined treatment.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},346367,1790882672,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},687197100911,"https://ap-avatar.wpscdn.com/avatar/a000239b6f1da00475?x-image-process=image/resize,m_fixed,w_180,h_180&k=1785132997149421697","Potent synthetic lethality between PLK1 and EYA family inhibitors in tumors of the central and peripheral nervous systems  \nChristopher B. Nelson,1,4 Jadon K. Wells,1,4 Ekaagra Kesarwani,1 Alexander P. Sobinoff,1 Madushan Fernando,1 Jixuan Gao, 1 Karen L. MacKenzie,1 Rebecca C. Poulos,1 Urwah Nawaz, 1 Xiang Wang,2 Heide L. Ford,3 and Hilda A. Pickett1  \n1Children’s Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, New South Wales 2145, Australia; 2Department of Chemistry, University of Colorado, Boulder, Colorado 80309, USA; 3Department of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, Colorado 80045, USA  \nThe Eyes Absent family of protein phosphatases (EYA1–4) is aberrantly expressed and tumor-promoting across many devastating cancers of neurological origin affecting both children and adults. It has recently been demonstrated that EYA1 and EYA4 promote tumor cell survival by increasing the active pool of Polo-like kinase 1 (PLK1) molecules. This discovery provides a rationale for the therapeutic combination of EYA inhibitors with direct, ATP-competitive PLK1 inhibitors. Here, we demonstrate potent loss of cell viability in response to combined EYAandPLK1 inhibition in cancer cell lines that overexpress EYA1 and/or EYA4, including in neuroblastoma and glioblastoma models. We identify decreases in PLK1 activity and RAD51 focus formation and increases in mitotic arrest and cell death as mechanistic contributors to combination sensitivity. Combined EYA and PLK1 inhibition is also effective in glioblastoma stem cell models that overexpress EYA1/EYA4 and specifically targets the cancer stem cell state. Finally, through multiomic correlational analysis, we identify high levels of theNuRD complex and SOX9 as contributors to combination treatment sensitivity. Overall, this work identifies a novel synthetic-lethal combination therapy with potential utility across a wide range of neurological cancers.  \n[Keywords: cancer stem cell; drug synergy; Eyes Absent family; glioblastoma; neuroblastoma; Polo-like kinase 1] Supplemental material is available for this article.  \nReceived August 19, 2025; revised version accepted September 16, 2025 .  \nDuring development, Eyes Absent 1–4 (EYA1–4) serve as integral components of the retinal determination gene network that contributes to cell fate determination across various tissues (Tadjuidje and Hegde 2013; Soni et al. 2021) . While expression of most of the EYA proteins is largely restricted in normal adult tissues, emerging evidence indicates that these proteins are frequently overexpressed and tumorigenic in cancers of both the peripheral and central nervous systems, including malignant peripheral nerve sheath tumors (Miller et al. 2010), neuroblastoma (Hansen et al. 2016), low-grade glioma/astrocytoma (Wen et al. 2017; Zhu et al. 2021), glioblastoma (Li et al. 2018; Kim et al. 2021; Zhang et al. 2021), and medulloblastoma (Eisner et al. 2015; Wolin et al. 2023; Hwang et al. 2024) . Monotherapy with pan-EYA family phosphatase inhibitors has been tested in glioblastoma and medulloblastoma xenograft models, where EYA inhibition has  \nbeen shown to increase survival (Zhang et al. 2021; Hwang et al. 2024) . However, targeted monotherapies almost always result in acquired resistance, and there is a growing appreciation for the need to identify rational combination therapies for effective cancer treatment (Mokhtari et al. 2017; Sabnis and Bivona 2019; Jin et al. 2023) .  \nPolo-like kinase 1 (PLK1) is an essential mitotic kinasethat functions during centrosome maturation, mitotic entry, checkpoint recovery, spindle formation, and other processes (Colicino and Hehnly 2018; Iliaki et al. 2021) . PLK1 is also an important cancer target for many of the same tumors as the EYA proteins, and direct, ATP-competitive PLK1 inhibitors are effective in preclinical models of glioblastoma (Lee et al. 2012; Danovi et al. 2013; Tandle et al. 2013; H","cbCaihlPxG9tItgE","https://ap.wps.com/l/cbCaihlPxG9tItgE","pdf",14784049,17,"English","# Background and rationale\n## EYA1–4 and PLK1 regulation\n## Therapeutic combination strategy\n# Experimental findings\n## Viability loss with combined inhibition\n## Mechanistic effects on PLK1 and RAD51\n## Effects in tumor and stem-cell models\n# Biomarker and sensitivity drivers\n## Multiomic correlational analysis\n## NuRD complex and SOX9","[{\"question\":\"What is the central hypothesis of the study?\",\"answer\":\"EYA family inhibitors are hypothesized to indirectly inhibit PLK1 by reducing the active PLK1 pool, thereby sensitizing tumors to direct ATP-competitive PLK1 inhibitors and producing synthetic lethality.\"},{\"question\":\"How does combined EYA and PLK1 inhibition affect cancer cells?\",\"answer\":\"The combination causes potent loss of cell viability, decreases PLK1 activity and RAD51 focus formation, and increases mitotic arrest and cell death in EYA-overexpressing cancer models.\"},{\"question\":\"Does the combination work in glioblastoma stem cell models?\",\"answer\":\"Yes. The combined EYA and PLK1 inhibition is effective in glioblastoma stem cell models that overexpress EYA1/EYA4 and it specifically targets the cancer stem cell state.\"},{\"question\":\"Which molecular features are linked to sensitivity to the combination?\",\"answer\":\"Multiomic correlational analysis identifies high levels of the NuRD complex and SOX9 as contributors to sensitivity to the combined treatment.\"}]","Potent synthetic lethality between PLK1 and EYA family inhibitors in tumors of the central and peripheral nervous systems - Research report | PDF",1790061119,43,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/964bdcbc5489f53de243b75232033730.webp",983,1272,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dc5629722f95fc735992216cf3ec2478.webp",982,1270,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f4436977e4639486c07b151e7aabef52.webp",981,1269,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4833512a3b44cce7b4cc2d367e69d7ea.webp",980,1268]